Traduction de «time 3 years » (Français → Néerlandais) :

Distinct energy programmation during brady-pacing and post shock Programmable minimal and maximal heart rate Activity sensor and rate response Rate Hysteresis Programmable AV delay after atrial sense or pace Anti-PMT algorithm Defibrillation Defibrillation or ATP VT/SVT discrimination algorithms Event Counters Heart Rate time interval diagnostics Stored intracardiac electrograms Distinct programmation of right/left ventricular stimulation 4 years warranty on longevity 3 years warranty on longevity
Distinct energy programmation during brady-pacing and post shock Programmable minimal and maximal heart rate Activity sensor and rate response Rate Hysteresis ProgrammableAV delay after atrial sense or pace Anti-PMT algorithm Defibrillation Defibrillation or ATP VT/SVT discrimination algorithms Event Counters Heart Rate time interval diagnostics Stored intracardiac electrograms Distinct programmation of right/left ventricular stimulation 4 years warranty on longevity 3 years warranty on longevity

Liste des abréviations utilisées ADN Acide désoxyribonucléique AST Aspartate amino transférase CI Cold ischemia CIT Cold ischemia time CSS Conseil Supérieur de la Santé DBD Donation after brain death or HBD DCD Donation after cardiac death or NHBD DGF Delayed graft function EC EuroCollins ECD Extended/expanded criteria donors ECMO Extracorporeal membrane oxygenation EVLP Ex vivo lung perfusion HBD Heart-beating donors or DBD HMP Hypothermic machine perfusion HOPE Hypothermic oxygenated perfusion HTK Histidine-tryptophane-ketoglutarate IRI Ischemia-reperfusion injury ISHLT International Society for Heart and Lung Transplantation L-FABP Liver type fatty acid-binding protein MP Machine perfusion NHBD Non-heart-beating donors NMP Normothermic machine perfusion OCS Organ case system OTS Organ transport system PEG Polyéthylène glycol PFC Perfluorocarbones PNF Primary non-function PGD Primary graft dysfunction QALY Quality-adjusted life years SCD Standard criteria donor SCS Static or simple cold storage SCOT® Solution de conservation d’organes et de tissus
Lijst van de gebruikte afkortingen ASAT Aspartaat-aminotransferase CI Cold ischemia CIT Cold ischemia time DBD Donation after brain death or HBD DCD Donation after cardiac death or NHBD DGF Delayed graft function DNA Desoxyribonucleïnezuur EC EuroCollins ECD Extended/expanded criteria donors ECMO Extracorporeal membrane oxygenation EVLP Ex vivo lung perfusion HBD Heart-beating donors or DBD HGR Hoge Gezondheidsraad HMP Hypothermic machine perfusion HOPE Hypothermic oxygenated perfusion HTK Histidine-tryptophane-ketoglutarate IRI Ischemia-reperfusion injury ISHLT International Society for Heart and Lung Transplantation L-FABP Liver type fatty acid-binding protein Long-Tx Longtransplantatie MP Machine perfusion NHBD Non-heart-beating donors NMP Normothermic machine perfusion OCS Organ case system OTS Organ transport system PEG Polyethyleenglycol PFK Perfluorkoolwaterstoffen PGD Primary graft dysfunction PNF Primary non-function QALY Quality-adjusted life years SCD Standard criteria donor SCOT® Solution de conservation d’organes et de tissus

Decision analytic model (time horizon 1 year) US Payer (third party payer or patient) Pharmacist advice alone Pharmacist advice+NRT patch Pharmacist advice+NRT gum Pharmacist advice+Buproprion Study funded by an American Pharmaceutical Association Foundation Incentive Grant
Decision analytic model (time horizon 1 year) US Payer (third party payer or patient) Pharmacist advice alone Pharmacist advice+NRT patch Pharmacist advice+NRT gum Pharmacist advice+bupropion Study funded by an American Pharmaceutical Association Foundation Incentive Grant

Dutch survival 1607 Britisch survival 1714 Belgian survival supplemented by French dataa 1460 Assumed lead time 3 years 1098
Dutch survival 1607 Britisch survival 1714 Belgian survival supplemented by French dataa 1460 Assumed lead time 3 years 1098 All QALYs minus 20% 1307 All QALYs plus 20% 1307 Stage II III IV -20 1307 Stage III IV -20 1307 Stage IV -20 1307

The medical risk of any stroke or death in the forthcoming five years in symptomatic persons of the NASCET/ECST trials with a stenosis of 50% (according to the NASCET method) was 21%. 14 That risk was further increased by male sex (23%), old age ( 75 y, 31%), time since last event (< 2 weeks, 32%) and diabetes.
The medical risk of any stroke or death in the forthcoming five years in symptomatic persons of the NASCET/ECST trials with a stenosis of 50% (according to the NASCET method) was 21%.[14] That risk was further increased by male sex (23%), old age ( 75 y, 31%), time since last event (< 2 weeks, 32%) and diabetes.